Autopsy report · NCT05261490

Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer

“A business decision was made by Pfizer to terminate and remove the Phase 2 expansion of this study for administrative reasons. The reason for study termination is not due to any safety concerns or requests from regulatory authorities.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 8 months before it started.
• Ran for about 1 year 6 months before it stopped.
• 10 participants enrolled.
• Results were posted on the registry 9 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Pfizer

Sponsor type

Industry

Conditions

Ovarian Cancer; Ovarian Neoplasms; Ovarian Carcinoma; Fallopian Tube Cancer; Epithelial Ovarian Cancer; Primary Peritoneal Carcinoma

Interventions

maplirpacept (PF-07901801); Pegylated Liposomal Doxorubicin (PLD)

Participants

10

Sites

18

Countries

United States

Trials that died the same way

• Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients
  “Pfizer made a business-related decision on 04May2017 to terminate study based on change in portfolio prioritization, and is not due to safety or efficacy.” (72% match in meaning)
• A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Healthy Males
  “Study recruitment was terminated on 14 June 2016 due to a Pfizer business decision. This study was not terminated for reasons of safety.” (70% match in meaning)
• A Study of PF-07260437 in Advanced or Metastatic Solid Tumors
  “Pfizer has made an internal business decision to not continue further development of PF-07260437. This decision was not due to major safety concerns or requests from any regulatory authorities.” (67% match in meaning)
• A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer
  “The study was terminated on June 24th, 2015 due to change in strategy of PF-03084014 development. There were no safety/efficacy concerns behind the decision.” (66% match in meaning)
• A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD
  “It has been made the strategic decision to terminate the study. This decision to terminate the study early is not being made for safety reasons.” (66% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.